Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...

The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...

As Pfizer’s strategic corporate venture capital arm, Pfizer Ventures invests globally in innovative biopharmaceutical companies advancing breakthrough medicines that have the potential to transform ...

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

The Pfizer Futures assessment is designed to help us better understand your potential and identify candidates who may thrive within Pfizer's values-driven culture and future talent pipeline As part of ...

For Washington residents, please visit our Washington Health Data Privacy Policy to review our privacy practices related to your health data.

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...

Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific ...

2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to ...